Premium
Reply
Author(s) -
Weng Jianping
Publication year - 2019
Publication title -
hepatology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.30553
Subject(s) - medicine , nonalcoholic fatty liver disease , liraglutide , sitagliptin , metformin , type 2 diabetes mellitus , fatty liver , type 2 diabetes , insulin glargine , gastroenterology , intensive care medicine , diabetes mellitus , disease , insulin , endocrinology
We sincerely thank Dr. Sikarin Upala for his interest in our article and for sharing his experience in the treatment of nonalcoholic fatty liver disease (NAFLD). NAFLD is prevalent in patients with type 2 diabetes mellitus (T2DM), yet only preliminary evidence are available on the effect of anti-diabetic agents to NAFLD in T2DM patients. According to clinical practice guidelines for NAFLD management (1,2) , no pharmacotherapies are approved for the treatment of NAFLD. There is neither proper therapy for patients with T2DM and NAFLD. So we designed this 26-week comparative trial, aiming to evaluate the efficacy and safety of liraglutide, sitagliptin, and insulin glargine as an add-on treatment to metformin in patients with T2DM and NAFLD. This article is protected by copyright. All rights reserved.